Hydrofarm Holdings Group, Inc. (“Hydrofarm” or the “Company”) (Nasdaq: HYFM), a leading independent manufacturer and distributor of branded hydroponics equipment and supplies for controlled ...
Positive FDA feedback confirms clear clinical pathway for BX011 targeting S. aureus in Diabetic Foot Infections, building on Company’s prior ...
Research and development (R&D) expenses for the three months ended September 30, 2025, were $5.3 million, compared to $6.0 million in the same three-month period of 2024 and a decrease from $6.2 ...
CARVYKTI® (ciltacabtagene autoleucel; cilta-cel) net trade sales of approximately $524 millionEC and U.S. FDA label updates for CARVYKTI® to ...
Lead candidate from mutant selective JAK2V617F JH2 inhibitor program advancing with IND filing expected in the first quarter of 2026Lead ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback